ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1835

Study on the Expression of NOD2 in Lupus Nephritis and Its Potential Signaling Pathway

Ou Jin, Chengcheng Hou, Qiuxia Li, Xi Zhang, Qiujing Wei, Hongyue Huang, Mingli Qiu and Jieruo Gu, Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Lupus nephritis, nod-like receptor (NLR) and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:  Nucleotide-binding oligomerization domain (NOD) – containing 2 (NOD2) is a NOD - like receptors (NLRs) which plays important role in immune regulation and inflammatory response. There are increasing evidences to show that NOD2 may contribute to the development of numerous auto inflammatory and autoimmune disorders. However, their role in lupus nephritis (LN) is not known. Here, we explored the role of NOD2 in LN.

Methods:  Immunohistochemistry was applied to observe the expression of NOD2 in renal biopsies. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the level of NOD2 mRNA in the biopsies. In vitro studies, HK-2 cells (renal tubular epithelial cell-line) were cultured with different inflammatory stimulation, western blot was used to investigate their expression of NOD2 and the following activation of MAPK pathway signals (ERK1/2, p38 and JNK), real-time qPCR was applied to observe the mRNA levels of downstream pro–inflammatory mediators (IL-1b, IL-8, MCP-1, TGF-b1, IL-6) .

Results:  (1) Immunohistochemistry staining demonstrated that the expression of NOD2 in LN is higher than that of normal control (P=0.002), and the mRNA level of NOD2 in renal tissue of LN patients was higher than that of normal control (P=0.001). (2) In vitro studies, the urine and serum from onset LN patients can significantly promote higher NOD2 expression in HK2 cells than that from healthy control (P<0.001). In addition, TGF-b1, LPS and muramyl dipeptide (MDP) can also induce higher NOD2 expression in HK2 cells (P<0.001, respectively). (3) The activation of NOD2 increased phosphorylation of ERK1/2, p38 and JNK. Moreover, the activation of NOD2 induced the release of pro–inflammatory mediators including IL-1b, IL-8, MCP-1, TGF-b1, IL-6.

Conclusion: Our study showed NOD2 expression was increased in LN patients. The activation of NOD2 can promote the activation of MAPK signaling pathway and release of downstream pro–inflammatory mediators. NOD2 may participate in the pathogenesis of LN. 


Disclosure: O. Jin, None; C. Hou, None; Q. Li, None; X. Zhang, None; Q. Wei, None; H. Huang, None; M. Qiu, None; J. Gu, None.

To cite this abstract in AMA style:

Jin O, Hou C, Li Q, Zhang X, Wei Q, Huang H, Qiu M, Gu J. Study on the Expression of NOD2 in Lupus Nephritis and Its Potential Signaling Pathway [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/study-on-the-expression-of-nod2-in-lupus-nephritis-and-its-potential-signaling-pathway/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/study-on-the-expression-of-nod2-in-lupus-nephritis-and-its-potential-signaling-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology